Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane, Claire Margolis, Diana Miao, Susana Miranda, David Dolling, Matthew Clarke, Claudia Bertan, Mateus Crespo, Gunther Boysen, Ana Ferreira, Adam Sharp, Ines Figueiredo, Daniel Keliher, Saud Aldubayan, Kelly P Burke, Semini Sumanasuriya, Mariane Sousa Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Larissa Sena Teixeira Mendes, Kent Mouw, Michael T Schweizer, Colin C Pritchard, Stephen Salipante, Mary-Ellen Taplin, Himisha Beltran, Mark A Rubin, Marcin Cieslik, Dan Robinson, Elizabeth Heath, Nikolaus Schultz, Joshua Armenia, Wassim Abida, Howard Scher, Christopher Lord, Alan D’Andrea, Charles L Sawyers, Arul M Chinnaiyan, Andrea Alimonti, Peter S Nelson, Charles G Drake, Eliezer M Van Allen, Johann S de Bono
PMCID: PMC6205373  PMID: 30382943

Original citation: J Clin Invest. 2018;128(10):4441–4453. https://doi.org/10.1172/JCI121924

Citation for this corrigendum: J Clin Invest. 2018;128(11):5185. https://doi.org/10.1172/JCI125184

Charles L. Sawyers’s conflict-of-interest statement was not included in the manuscript. The correct statement is below.

CLS reports coinventorship on patents on enzalutamide (US 7,709,517B2; US 8,183,274B2), licensed to Pfizer, and apalutamide (US 8,445,507; US 9,388,159), licensed to Johnson & Johnson. CLS serves on the board of directors of Novartis, is a cofounder of ORIC Pharmaceuticals, and is a science advisor to Agios, BeiGene, Blueprint Medicines, Column Group, Foghorn Therapeutics, Housey Pharmaceutical Research Laboratories, Nextech, KSQ Therapeutics, Petra Pharma Corp., and PMV Pharma. CLS was a cofounder of Seragon Pharmaceuticals, purchased by Genentech/Roche in 2014.

The authors regret the error.

Version 1. 11/01/2018

Print issue publication

Footnotes

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES